Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cybin Inc (NY: CYBN )

0.2640 -0.0006 (-0.23%)
Official Closing Price Updated: 8:00 PM EDT, Aug 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,117,264
Open 0.2586
Bid (Size) 0.2516 (35)
Ask (Size) 0.2610 (21)
Prev. Close 0.2646
Today's Range 0.2450 - 0.2640
52wk Range 0.2400 - 0.7380
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Holds Initial Breakthrough Therapy Meeting with FDA, Plans for CYB003 Phase 3 Trial
Via Investor Brand Network
Exposures Product Safety
Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder
From Cybin Inc.
Via Business Wire

Performance

YTD
-34.00%
-34.00%
1 Month
-14.56%
-14.56%
3 Month
-24.57%
-24.57%
6 Month
-21.71%
-21.71%
1 Year
-19.39%
-19.39%

More News

Read More
CYBN Stock Earnings: Cybin Beats EPS for Q1 2024
Via InvestorPlace
BioMedNewsBreaks — Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Releases Q1 2025 Financial Results, Business Highlights
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
CYBN Stock Earnings: Cybin Beats EPS for Q4 2023
Via InvestorPlace
Cybin Reports First Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO to Participate in a Fireside Chat at Upcoming Conference
Via Investor Brand Network
Cybin to Participate in the Canaccord Genuity 44th Annual Growth Conference
From Cybin Inc.
Via Business Wire
EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves
Via Benzinga
3 Biotech Stocks That Could Make Your Summer Unforgettable
Via InvestorPlace
Cybin Inc. Stands Strong As A Remaining Force To Prove Benefits Of Psychedelic Therapeutics ($CYBN)
Via AB Newswire
Exposures Product Safety
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Sees “Swell” of Insider Investments, Upgrade in Ranking after Positive Year-End Report
Via Investor Brand Network
Psychedelic Picks: 3 Trippy Stocks Aiming for Out-of-This-World Returns
Via InvestorPlace
3 Psychedelic Stocks to Buy on the Dip: Summer 2024
Via InvestorPlace
Biopharma Co. Cybin Reports $78M Loss Amid Accelerating Expansion In Psychedelic Therapies, Drug Development
Via Benzinga
Cybin Reports Fiscal Year 2024 Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO Featured Presenter at Upcoming H.C. Wainwright Neuro Perspectives Virtual Conference
Via Investor Brand Network
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Releases FY Financial Report, Business Update
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
From Cybin Inc.
Via Business Wire
Latest Executive Cannabis Changes You Should Know About: Curaleaf, Planet 13 Elect Directors And More
Via Benzinga
Topics Cannabis
Exposures Cannabis
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Strategic Appointment of Dr. Atul Mahableshwarkar
Via Investor Brand Network
Exposures Product Safety
Cybin Appoints Dr. Atul Mahableshwarkar M.D., as Senior Vice President, Clinical Development
From Cybin Inc.
Via Business Wire
Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment
Via Benzinga
Exposures Product Safety
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Participation at Interdisciplinary Conference on Psychedelic Research 2024
Via Investor Brand Network
Cybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024
From Cybin Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.